Once thrombi have formed as part of the pathology defining myocardial infarction, ischemic
stroke, peripheral arterial disease, deep venous thrombosis or other embolic disorders, the …

Highlights•Despite the availability of revascularization strategies the care of heart disease
and stroke patients remains challenging.•There is an unmet clinical need to explore novel …

Thrombolytic therapy by infusion of analogs of tissue plasminogen activator (tPA), other
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …

Stroke burden is substantially increasing but current therapeutic drugs are still far from ideal.
Here we highlight the vast potential of staphylokinase as an efficient, fibrin-selective …

Vascular occlusion is one of the major causes of mortality and morbidity. Blood vessel
blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep …

Improvements may be realized as a result of increased efficacy, greater safety or reduced
cost. One approach to increasing the efficacy of thrombolytic therapy has been the …

Acute myocardial infarction and ischemic stroke are the two main causes of death and
disability in our Western societies. Thrombolytic therapy of these diseases is based on the …

Thrombosis is a life‐threatening pathological condition in which blood clots form in blood
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …

The plasminogen activating enzyme system has been exploited and harnessed for
therapeutic, mainly thrombolytic benefit for many years. While plasminogen activator-based …

Formation of blood clumps inside vessels which restrict blood circulation throughout
circulatory system is known as thrombosis. This leads to origin of numerous abnormalities …